Xavier Valencia
Head of IBD Franchise Enveda Biosciences Inc.
Xavier brings an exceptional track record across multiple therapeutic areas and modalities. Most recently at Ventus Therapeutics, he led the development of a brain-penetrant NLRP3 inhibitor and a first-in-class cGAS inhibitor. His career spans leadership roles in gene & cell therapy (Tr1X), small molecules (Strongbridge Biopharma), and biologics (Boston Pharmaceuticals)—driving programs all the way from IND submission through to BLA/NDA filings
Seminars
Thursday 2nd April 2026
Roundtable Discussion: Delivering Faster & More Reliable IBD Trials Using Real-World Evidence, Smarter Recruitment & Meaningful Endpoints
11:45 am
- Explore innovative recruitment and retention strategies that have successfully reduced trial delays and improved reliability
- Share experiences using real-world data and predictive tools to identify ideal candidates and assess the impact on response rates and trial costs
- Examine how real-world evidence can be strategically applied to design endpoints in IBD trials that are clinically meaningful and aligned with regulatory and commercialization goals
- Address challenges of data fragmentation in IBD research by improving access to comprehensive datasets including biomarkers, histology, and patient-reported outcomes
